TrialBritish journal of cancer2010

Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value.

A Michlmayr et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.